Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CCR4 | P51679 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888958 | 0.85 | CCR2 (0.60) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL306286 | 0.85 | CCR2 (0.60) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL307108 | 0.83 | CCR2 (0.57) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL306979 | 0.83 | CCR2 (0.63) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL13610261 | 0.81 | CYP2C9 (0.58) | CCR2KCNH2CYP2C9CYP3A4 | |
| SCHEMBL306044 | 0.80 | CCR2 (0.64) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10223240 | 0.80 | CCR2 (0.61) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10222546 | 0.79 | CCR2 (0.63) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10223239 | 0.79 | CCR2 (0.54) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL13611012 | 0.78 | CCR2 (0.57) | CCR2KCNH2CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093247-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | CCR2 1/4885KCNH2 4574/4885CYP2C9 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.